52 related articles for article (PubMed ID: 16263411)
1. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
Ellingsen EB; Bjørheim J; Gaudernack G
Curr Opin Oncol; 2023 Mar; 35(2):100-106. PubMed ID: 36700456
[TBL] [Abstract][Full Text] [Related]
3. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Ellingsen EB; Mangsbo SM; Hovig E; Gaudernack G
Front Immunol; 2021; 12():682492. PubMed ID: 34290704
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer Immunotherapies Targeting Telomerase.
Negrini S; De Palma R; Filaci G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806719
[TBL] [Abstract][Full Text] [Related]
6. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Martin Lluesma S; Graciotti M; Chiang CL; Kandalaft LE
Vaccines (Basel); 2018 Nov; 6(4):. PubMed ID: 30477198
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of replicative immortality.
Yaswen P; MacKenzie KL; Keith WN; Hentosh P; Rodier F; Zhu J; Firestone GL; Matheu A; Carnero A; Bilsland A; Sundin T; Honoki K; Fujii H; Georgakilas AG; Amedei A; Amin A; Helferich B; Boosani CS; Guha G; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Bhakta D; Halicka D; Niccolai E; Aquilano K; Ashraf SS; Nowsheen S; Yang X
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S104-S128. PubMed ID: 25869441
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
9. Is telomerase a viable target in cancer?
Buseman CM; Wright WE; Shay JW
Mutat Res; 2012 Feb; 730(1-2):90-7. PubMed ID: 21802433
[TBL] [Abstract][Full Text] [Related]
10. Telomerase and the endocrine system.
Pacini F; Cantara S; Capezzone M; Marchisotta S
Nat Rev Endocrinol; 2011 Mar; 7(7):420-30. PubMed ID: 21448143
[TBL] [Abstract][Full Text] [Related]
11. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.
Suso EM; Dueland S; Rasmussen AM; Vetrhus T; Aamdal S; Kvalheim G; Gaudernack G
Cancer Immunol Immunother; 2011 Jun; 60(6):809-18. PubMed ID: 21365467
[TBL] [Abstract][Full Text] [Related]
12. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.
Morrison R; Schleicher SM; Sun Y; Niermann KJ; Kim S; Spratt DE; Chung CH; Lu B
J Oncol; 2011; 2011():941876. PubMed ID: 20981352
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of leukemic stem cell pathways.
Chumsri S; Matsui W; Burger AM
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6549-54. PubMed ID: 18006753
[TBL] [Abstract][Full Text] [Related]
14. Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH
Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
[TBL] [Abstract][Full Text] [Related]
15. Telomerase and its potential for therapeutic intervention.
Phatak P; Burger AM
Br J Pharmacol; 2007 Dec; 152(7):1003-11. PubMed ID: 17603541
[TBL] [Abstract][Full Text] [Related]
16. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
Danet-Desnoyers GA; Luongo JL; Bonnet DA; Domchek SM; Vonderheide RH
Exp Hematol; 2005 Nov; 33(11):1275-80. PubMed ID: 16263411
[TBL] [Abstract][Full Text] [Related]
17. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
18. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
[TBL] [Abstract][Full Text] [Related]
19. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
